{'fraction_non_alphanumeric': 0.025869759143621766, 'fraction_numerical': 0.01159678858162355, 'mean_word_length': 5.523255813953488, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
METHOD FOR OCCUPATIONAL SKIN DOSE ESTIMATION IN UPPER EXTREMITY 131I-MIBG CONTAMINATION

This study examines upper extremity skin contamination of nuclear medicine and radiation safety staff during 131I-Metaiodobenzylguanidine (MIBG) therapy. Utilizing retrospective data, a methodology for performing a rapid assessment of the radiation dose to the skin of the upper extremities is presented. Using the skin contamination measurements and calculated skin dose for each contamination incident at our facility, a conversion factor (XE) was derived that estimates skin dose (DE) based on the initial contamination measurement. This methodology yields an estimate of the final skin dose accounting for radioactive decay, decontamination and other factors, such as skin sloughing. As a standard practice multiple time-point measurements from initial contamination to background should be used to calculate the total attributable skin dose. However, to provide an early projection of the expected skin dose, the dose can be reasonably estimated to be <0.10% mSv cpm-1 (10% mrem cpm-1) of the initial contamination measurement.